LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Enzyme Found to Trigger the Immune System, Providing Clues on Alzheimer’s-Related Protein

By LabMedica International staff writers
Posted on 13 Jan 2015
New findings with a specific enzyme could provide more clues on presenilin functions, in addition to providing a better determination into how the immune system is controlled.

Already known to cut proteins, the enzyme SPPL3 (signal peptide peptidase-like 3) appears to have additional talents, according to new data. In its newly discovered role, SPPL3 has been found to function without chopping proteins to activate T cells, the immune system’s combat forces. Because its structure is similar to that of presenilin enzymes, which have been implicated in Alzheimer’s Disease (AD), the researchers hope their new findings will provide better treatment options for the debilitating disorder.

A summary of their findings was published on December 22, 2014, in the journal Molecular and Cellular Biology. “No one could have predicted that SSPL3 was involved in T cell activation,” stated Joel Pomerantz, PhD, an associate professor of biological chemistry at Johns Hopkins University (JHU; Baltimore, MD, USA). “It walks like a duck and quacks like a duck, but its duck-like abilities don’t come into play here.”

T cells are immune system cells that destroy invading cells and help activate other immune cells. When a foreign protein binds to a receptor protein on the outside of a T cell, a signal relay system is activated. It finishes when a protein called NFAT (nuclear factor of activated T cells) moves to the nucleus and triggers a number of genes to effectively prepare the T cell for battle. Some of what happens in between is known, however, Dr. Pomerantz and his colleagues wanted to find more players in the process.

The researchers searched for proteins that could increase NFAT’s activity and found SPPL3, an enzyme that proved essential to NFAT’s activation but had never before been implicated in immune system function. Additional testing accurately placed SPPL3 within the sequence of events that lead to NFAT activation.

SPPL3 lives in the membrane of the endoplasmic reticulum (ER), a ruffled, membrane-bound compartment inside the cell that helps process new proteins, where it seems to encourage interactions between STIM1 and Orai1, two known components of the NFAT signal relay system. However, SPPL3 was found to accomplish this without using its enzymatic, or protein-cutting, abilities. It also encourages the release of calcium from the ER, which contributes to the signaling system though it is unclear whether this is something it does directly or indirectly. “SPPL3 is a relatively uncharacterized protein that had never before been implicated in immune system function,” said Dr. Pomerantz. “It opens up a whole new set of scientific questions.”

Dr. Pomerantz believes that SPPL3 could be used as a drug target to either augment the activation of T cells in immunodeficient individuals or to suppress it in those with overactive immune systems. He also plans to study the ability of SPPL3 to mediate the influx of calcium into the cell and the release of calcium from the ER, since calcium is key to the functioning of many cell signaling networks.

Related Links:

Johns Hopkins University


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Sample Transportation System
Tempus1800 Necto

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more